文献速递胸部技术与安全CT

高保真超分辨率CT影像组学预测肺腺癌EGFR突变

High-fidelity super-resolution CT radiomics for non-invasive EGFR mutation prediction in lung adenocarcinoma: a multi-center pooled analysis.
PubMed 文献 · Radiol Med · 2026-06-24

针对肺腺癌EGFR突变无创预测,该多中心回顾性研究纳入373例患者,采用RCAN将CT图像重建为1024×1024矩阵后提取影像组学特征。SR增强模型在测试集AUC由原始分辨率0.60提升至0.84,联合列线图AUC达0.86,提示超分辨率重建可改善分子表型预测。

要点

  • SR增强影像组学测试集AUC达0.84,显著高于原始分辨率0.60,可用于肺腺癌EGFR突变无创初筛参考。
  • 联合列线图AUC为0.86且校准与临床净获益更优,报告中可提示结合临床预测因素综合判断。
  • glszm_ZoneVariance是超分辨率重建后最主要预测特征,阅片时需关注瘤内异质性相关纹理表现。

核心结论

  • RCAN驱动的超分辨率重建可弥补CT分辨率限制,捕捉肺腺癌EGFR突变相关的细粒度影像基因组学特征。
  • SR增强影像组学框架在多中心及不同组织学亚型间表现稳定,具备无创分子表型决策支持的潜力。

研究设计与样本

  • 回顾性多中心汇总分析,共纳入373例肺腺癌患者,训练集298例,测试集75例。
  • CT图像经RCAN重建为1024×1024矩阵以恢复潜在高频纹理。
  • 采用ComBat协调、基于ICC的保真度过滤及LASSO回归标准化流程提取并筛选分辨率不变特征。
  • 评估五种机器学习分类器,并将SR增强影像组学标签与临床预测因素整合为联合列线图。

关键影像表现/征象

  • glszm_ZoneVariance为超分辨率重建后最主要预测特征,提示SR重建可显示与瘤内异质性相关的高频纹理信息。

诊断标准与关键数值

  • SR增强模型测试集AUC为0.84(95% CI: 0.75-0.93),显著优于原始分辨率基线的0.60(95% CI: 0.47-0.74),P<0.001。
  • 联合列线图AUC为0.86(95% CI: 0.78-0.94),校准与临床净获益优于单一模型。
  • 模型在不同影像中心间一致性检验P=0.555,且在组织学亚型间表现一致。

临床应用与阅片要点

  • 对疑似肺腺癌需行EGFR分子检测的患者,超分辨率重建后影像组学模型可作为无创辅助决策工具。
  • 阅片时对瘤内异质性明显的病灶,可结合影像组学标签与临床预测因素综合评价EGFR突变概率。
  • 该模型依赖1024×1024矩阵重建与标准化影像组学流程,运行前需匹配相应后处理条件。

局限性

  • 研究为回顾性设计,存在选择偏倚与混杂风险。
  • 测试集样本量仅75例,模型泛化能力需在更大样本及前瞻性队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To develop and validate a high-fidelity super-resolution (SR)-enhanced radiomics framework using a Residual Channel Attention Network (RCAN) for non-invasive EGFR mutation prediction in lung adenocarcinoma (LUAD).

METHODS: This retrospective multi-center study included 373 patients, partitioned into training (n = 298) and testing (n = 75) sets. CT images were reconstructed to a 1024 × 1024 matrix via RCAN to restore latent high-frequency textures. A standardized pipeline-including ComBat harmonization, ICC-based fidelity filtering, and LASSO regression-was employed to extract and select resolution-invariant features. Five machine learning classifiers were evaluated, and a combined nomogram integrated the SR-enhanced signature with clinical predictors. Model performance was assessed using AUC, DeLong tests, and decision curve analysis (DCA), with interpretability provided by SHAP analysis.

RESULTS: The SR-enhanced model significantly outperformed the original-resolution (OR) baseline, increasing the AUC from 0.60 (95% CI: 0.47-0.74) to 0.84 (95% CI: 0.75-0.93) in the testing set (P < 0.001). Consistent performance was maintained across imaging centers (P = 0.555) and histological subtypes. The combined nomogram achieved a robust AUC of 0.86 (95% CI: 0.78-0.94), demonstrating superior calibration and clinical net benefit. SHAP analysis revealed that glszm_ZoneVariance-a marker of intratumoral heterogeneity-was the predominant predictor revealed via SR reconstruction.

CONCLUSION: RCAN-driven SR reconstruction effectively addresses CT resolution limitations, capturing fine-grained radiogenomic signatures critical for molecular phenotyping. This high-fidelity framework offers a robust, non-invasive decision-support tool for personalized precision oncology in LUAD.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Liu, Zhang, Li, et al. High-fidelity super-resolution CT radiomics for non-invasive EGFR mutation prediction in lung adenocarcinoma: a multi-center pooled analysis. Radiol Med. 2026. PMID: 42340655. doi:10.1007/s11547-026-02229-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。